KEYTRUDA is the first and only immunotherapy-based regimen to show a statistically significant and clinically meaningful improvement in overall survival
Total investment incurred for setting up the new R&D Rs 250 crore
Fluoxetine Tabs 60 mg approval solidifies the company's position in the molecule by complementing the recent approval in April 2024 for Fluoxetine 10 mg and 20 mg tablets and Fluoxetine capsules
Both the products are Gadolinium based Magnetic Resonance Imaging (MRI) contrast agents and will be the first set of contrast agent products in Zydus’ injectable portfolio for the US market
The USFDA inspection focused on evaluating the facility's adherence to global regulatory requirements and best practices
The wP-IPV-based hexavalent vaccination is an innovative immunization alternative to the current pentavalent and standalone IPV vaccines
Secretary Vaidya Rajesh Kotecha has urged senior officials to strive for the successful attainment of targets during the campaign
Increases efficiency by 70% compared to stainless steel or glass manufacturing methods
A new initiative to contribute to enhancing drug discovery capabilities in the field of gene and cell therapy in Japan
Jubilant HollisterStier is a subsidiary of Jubilant Pharma Holding
Subscribe To Our Newsletter & Stay Updated
